Source: Benzinga

Merck: Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer

Merck's Phase 3 KEYNOTE-C93 trial showed Keytruda improved progression-free survival over chemotherapy in advanced endometrial cancer.read more

Read full article »

Merck's Competitors | Merck's News | Merck's Financials

Followers on Owler

31,568

Annual Revenue

$50-100B

Employees

50-100K

Chairman & CEO

Robert M. Davis

CEO Approval Rating

61/100

Merck is a New Jersey-based multinational biopharmaceutical company that develops and commercializes novel therapeutics and vaccines for the treatment of a range of diseases.